Elisabeth has over 20 years’ experience in the Pharmaceutical industry where she has held senior leadership roles from sales & marketing to portfolio strategy and to R&D management. She brings vast experience of managing international teams and has a proven track record of delivering innovation and new technology introduction from concept to implementation.
Prior to co-founding Clexio, Elisabeth was Senior Vice President of InnoTech, a Specialty R&D unit at Teva Pharmaceuticals in charge of developing new drugs and drug-device combinations.
By applying emerging technologies and next generation development techniques the team generated a pipeline of over a dozen novel therapeutics.
Before InnoTech, she was SVP Global Generic R&D at Teva Pharmaceuticals, leading a unit of more than 1,000 employees responsible for developing the company’s global generic pipeline. During this period, she led the R&D network transformation towards complex technologies and high value products.
In addition, under Elisabeth’s leadership as VP Global Sales & Marketing for Teva API Division (Active Pharmaceutical Ingredients) the unit’s sales performance increased organically from $250M to $600M annually.
Elisabeth holds an Master of Science from Ecole Centrale Paris, one of the leading Engineering Universities in France.
Elisabeth has a passion for finding solutions to health problems and reducing patients suffering.